Acrivon Therapeutics, Inc. (ACRV) Tops Q3 EPS by 69c
Tweet
Share
E-mailGet Alerts ACRV Hot Sheet
Join SI Premium – FREE
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q3 EPS of ($0.47), $0.69 better than the analyst estimate of ($1.16).
For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Macquarie favors BSL, RWC, REH in Australian earnings season
- Tenon Medical (TNON) Misses Q2 EPS by 395c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
